Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > TIGIT class of checkpoint inhibitors fails with Keytruda

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 09, 2023 6:30pm

134 Views

Post# 35489448

RE:RE:RE:RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda

You have no way of knowing what big investors think, nor what they want to buy from the company.

You have no way of knowing whether the results are impressing people, except to look at the results, which are impressive.

The share price will stay low until progress is announced.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles